

ARTICLE OPEN



Circulating metabolites modulated by diet are associated with depression

Ashley van der Spek^{1,2,33}, Isobel D. Stewart^{3,33}, Brigitte Kühnel^{4,5,33}, Maik Pietzner^{3,6,7,33}, Tahani Alshehri^{8,33}, Friederike Gauß⁹, Pirro G. Hysi¹⁰, Siamak MahmoudianDehkordi¹¹, Almut Heinken^{12,13}, Annemarie I. Luik¹, Karl-Heinz Ladwig^{5,14}, Gabi Kastenmüller^{15,16}, Cristina Menni¹⁰, Johannes Hertel^{12,17}, M. Arfan Ikram¹, Renée de Mutsert⁸, Karsten Suhre¹⁸, Christian Gieger^{4,5,16}, Konstantin Strauch^{19,20}, Henry Völzke²¹, Thomas Meitinger^{22,23}, Massimo Mangino¹⁰, Antonia Flaquer^{19,20}, Melanie Waldenberger^{4,5,24}, Annette Peters^{4,5,24,25}, Ines Thiele^{12,26,27}, Rima Kaddurah-Daouk^{11,28,29}, Boadie W. Dunlop³⁰, Frits R. Rosendaal⁸, Nicholas J. Wareham³, Tim D. Spector¹⁰, Sonja Kunze^{4,5,34}, Hans Jörgen Grabe^{17,34}, Dennis O. Mook-Kanamori^{31,34}, Claudia Langenberg^{3,6,34}, Cornelia M. van Duijn^{1,32,34} and Najaf Amin^{1,32,34}✉

© The Author(s) 2023

Metabolome reflects the interplay of genome and exposome at molecular level and thus can provide deep insights into the pathogenesis of a complex disease like major depression. To identify metabolites associated with depression we performed a metabolome-wide association analysis in 13,596 participants from five European population-based cohorts characterized for depression, and circulating metabolites using ultra high-performance liquid chromatography/tandem accurate mass spectrometry (UHPLC/MS/MS) based Metabolon platform. We tested 806 metabolites covering a wide range of biochemical processes including those involved in lipid, amino-acid, energy, carbohydrate, xenobiotic and vitamin metabolism for their association with depression. In a conservative model adjusting for life style factors and cardiovascular and antidepressant medication use we identified 8 metabolites, including 6 novel, significantly associated with depression. In individuals with depression, increased levels of retinol (vitamin A), 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) (lecithin) and mannitol/sorbitol and lower levels of hippurate, 4-hydroxycoumarin, 2-amino-octanoate (alpha-aminocaproic acid), 10-undecenoate (11:1n1) (undecylenic acid), 1-linoleoyl-GPA (18:2) (lysophosphatidic acid; LPA 18:2) are observed. These metabolites are either directly food derived or are products of host and gut microbial metabolism of food-derived products. Our Mendelian randomization analysis suggests that low hippurate levels may be in the causal pathway leading towards depression. Our findings highlight putative actionable targets for depression prevention that are easily modifiable through diet interventions.

Molecular Psychiatry (2023) 28:3874–3887; <https://doi.org/10.1038/s41380-023-02180-2>

¹Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands. ²SkylineDx B.V., Rotterdam, The Netherlands. ³MRC Epidemiology Unit, University of Cambridge, Cambridge, UK. ⁴Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, D-85764 Neuherberg, Germany. ⁵Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, D-85764 Neuherberg, Germany. ⁶Precision Healthcare University Research Institute, Queen Mary University of London, London, UK. ⁷Computational Medicine, Berlin Institute of Health at Charité, Universitätsmedizin Berlin, Berlin, Germany. ⁸Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands. ⁹Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Str., 17475 Greifswald, Germany. ¹⁰Department of Twins Research and Genetic Epidemiology, Kings College London, London, UK. ¹¹Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA. ¹²School of Medicine, University of Galway, University Road, Galway, Ireland. ¹³Inserm UMRS 1256 NGERE – Nutrition, Genetics, and Environmental Risk Exposure, University of Lorraine, Nancy, France. ¹⁴Department of Psychosomatic Medicine and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. ¹⁵Institute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, D-85764 Neuherberg, Germany. ¹⁶German Center for Diabetes Research (DZD e.V.), D-85764 Neuherberg, Germany. ¹⁷Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Ellernholzstrasse 1-2, 17489 Greifswald, Germany. ¹⁸Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Education City, PO 24144 Doha, Qatar. ¹⁹Institute of Genetic Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, D-85764 Neuherberg, Germany. ²⁰Chair of Genetic Epidemiology, IBE, Faculty of Medicine, LMU, Munich, Germany. ²¹Institute of Community Medicine, University Medicine Greifswald, Walter-Rathenau Str. 48, 17475 Greifswald, Germany. ²²Institute of Human Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, D-85764 Neuherberg, Germany. ²³Institute of Human Genetics, Technische Universität München, Munich, Germany. ²⁴German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. ²⁵Ludwig-Maximilians-Universität München, IBE-Chair of Epidemiology, Munich, Germany. ²⁶Division of Microbiology, University of Galway, Galway, Ireland. ²⁷APC Microbiome, Ireland, Ireland. ²⁸Duke Institute of Brain Sciences, Duke University, Durham, NC, USA. ²⁹Department of Medicine, Duke University, Durham, NC, USA. ³⁰Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, US. ³¹Department of Clinical Epidemiology, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands. ³²Nuffield Department of Population Health, University of Oxford, OX3 7LF Oxford, UK. ³³These authors contributed equally: Ashley van der Spek, Isobel D. Stewart, Brigitte Kühnel, Maik Pietzner, Tahani Alshehri. ³⁴These authors contributed equally: Sonja Kunze, Hans Jörgen Grabe, Dennis O Mook-Kanamori, Claudia Langenberg, Cornelia M van Duijn, Najaf Amin. ✉email: najaf.amin@ndph.ox.ac.uk

Received: 1 July 2022 Revised: 3 July 2023 Accepted: 3 July 2023

Published online: 26 July 2023

INTRODUCTION

Depression is one of the most common psychiatric disorders with an average lifetime prevalence of 11–15% [1]. A sharp increase in the prevalence of depression worldwide (33.7%; confidence interval 27.5–40.6) has been observed during the recent COVID-19 pandemic [2]. However, as the molecular mechanisms underlying depression remain elusive, the current treatment options for depression remain ineffective [3, 4]. The heritability of depression is estimated to be around 40% [5]. Several small effect (odds ratio <1.05) non-coding genetic variants have been identified to be associated with depression [6] but their contribution to the pathogenesis of depression remains unclear. There is also a range of environmental risk factors for morbidity including low education, diet and smoking [7]. There is increasing evidence that diet influences mood [8] by modulating the gut microbiome [9]. High consumption of fresh fruits, vegetables, whole grain, fish, and foods rich in antioxidants has been linked to improved gut health [9] and decreased risk of depression, while consumption of red and/or processed meat, refined grains, sweets and high-fat products is associated with increased risk of depression [10]. Large meta-analysis of clinical trials suggests that dietary interventions significantly reduce depressive symptoms, particularly in women [11] and the risk of several cardio-vascular diseases [12–14] that cluster strongly with depression [15].

Metabolome captures the downstream effects of genes, lifestyle factors such as diet, pathology and medication use and hence provides a useful tool to uncover biological mechanisms underlying complex diseases [16–18]. A novel hypothesis why circulating metabolites may be involved in depression is that these metabolites are involved in the gut-brain axis, i.e., the bi-directional signaling between the gut, its microbiome and the brain [19, 20]. Our study of 5283 patients with depression and 10,145 controls from nine Dutch cohorts [21] using a proton Nuclear Magnetic Resonance (NMR) metabolomics platform identified 21 cardiometabolic metabolites including apolipoproteins, very-low-density and high-density lipoprotein cholesterol (VLDLs and HDLs), di- and triglycerides, fatty acids, acetate, glycoprotein acetyls, tyrosine, and isoleucine [21]. Using the same metabolomics platform in the UK Biobank ($n > 63,000$), we confirmed most of these findings including the shift in the VLDL and HDL sub-fractions observed in depressed individuals in addition to finding disruption in the tricarboxylic acid (TCA) cycle - low citrate and high pyruvate levels in depressed individuals [22]. We further showed that the host gut microbiome partly explains the shift in VLDLs and HDLs observed in depressed individuals and that increase in VLDLs and changes in fatty acids are more likely to be a consequence of the disease [22]. These large-scale metabolomics studies are a major leap forward in understanding the pathogenesis in addition to identifying potential biomarkers and therapeutic targets for the disease. However, the NMR-based Nightingale platform is limited in the number of compounds measured and the metabolic pathways they cover, thus limiting the discovery of more diverse pathways. On the other hand, studies that have used larger mass spectrometry based metabolic platforms are small and have often resulted in false positive associations and inconsistent findings due to confounding bias resulting from the unaccounted for differences in lifestyle factors and medication use between cases and controls [23]. Some consensus is building that depression is associated with increased levels of glutamate, lactate, alanine, isobutyrate and sorbitol and with decreased levels of kynurenine, gamma aminobutyric acid (GABA), phenylalanine, tyrosine, creatinine, hypoxanthine, leucine, tryptophan, N-methylnicotinamide, β -aminoisobutyric acid, hippurate, amino-ethanol and malonate [23]. Again, whether these are causal associations or merely a consequence of the disease is not clear.

In the current study, using an untargeted mass spectrometry-based metabolomics (Metabolon) that measures over 800 compounds in a large sample ($n = 13,596$), we aim to 1) identify

robust potential metabolic biomarkers of depression by minimizing confounding bias; 2) Elucidate causal relationships to identify possible therapeutic targets; 3) Study the association of major dietary sources of the metabolites with depression, 4) Study the impact of different types of antidepressant therapy on the (potentially causal) associated metabolites, and finally 5) identify the gut microbiota involved in the metabolism of the identified metabolites (Fig. 1).

METHODS

We first perform a metabolome-wide association analysis of depression in 13,596 individuals from five European cohorts, characterized for metabolomics using mass-spectrometry-based Metabolon platform analysing 806 metabolites that cover a wide range of metabolic pathways (Fig. 1). We build a conservative model adjusting for most known confounders including lifestyle factors and medication use as suggested by MacDonald et al. [23]. Next, we use Mendelian Randomization to infer causal associations using the NIHR BioResource (NBR) and publicly available summary statistics of the largest genome-wide association study (GWAS) of depression [6]. We then identify the major food sources of the metabolites using previous literature and study the association of these food sources with depression in the UK Biobank study ($N < 500,000$). For metabolites that show potentially causal relationship with depression, we study the impact of antidepressant therapy in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study. Finally, we integrate our findings with those of the Virtual Metabolic Human (VMH) and Assembly of Gut Organisms through Reconstruction and Analysis (AGORA2) databases to identify gut microbiota involved in the metabolism of the identified metabolites (Fig. 1).

Study populations

Metabolites association analysis. The association analysis of metabolite levels with depression was performed in 13,596 participants separately recruited in five different cohort studies (Table 1). The following cohort studies were included: the Rotterdam Study, the Study of Health in Pomerania (SHIP-TREND), the Cooperative Health Research in the Region of Augsburg (KORA) study, the European Prospective Investigation into Cancer (EPIC)-Norfolk Study, and the Netherlands Epidemiology of Obesity (NEO) study. Detailed information on these cohorts is provided in the Supplementary Materials. All participants provided written informed consent, studies were approved by their local ethics committees and conformed to the principles of the declaration of Helsinki. Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Inference of causal relationships using Mendelian Randomization (MR). To select instruments/proxies for metabolites for MR we used the results of the GWAS performed using the NBR - Rare Disease Study is a multi-center whole-exome and whole-genome sequencing study including up to 13,600 patients (<http://bioresource.nihr.ac.uk/rare-diseases/rare-diseases/>). The NBR-Rare Diseases study was approved by the East of England Cambridge South national research ethics committee (REC) under reference number: 13/EE/0325. The inclusion and exclusion criteria, as well as other steps of quality control, adjustment and transformations followed the same analytical steps as described before [24].

Identification and association of major dietary sources of the depression-associated metabolites. Major dietary sources of the depression-associated metabolites were identified through literature search. Association of depression with the dietary sources of the depression-associated metabolites was performed in the UK Biobank study. UK Biobank is a prospective cohort study including ~500,000 participants aged 40–69 years at baseline recruited between 2006 and 2010. The aim of the study is to investigate the effects of genetic and environmental factors on the risk of common multifactorial diseases. Participants have provided a detailed information on lifestyle, medical history and nutritional habits; basic variables such weight, height, blood pressure etc. were measured; and blood and urine samples were taken. Detailed information about the cohort is provided in the Supplementary Materials. The current study is a part of the UKB project 54520.

Impact of anti-depressant therapy on depression-associated (causal) metabolites. The effects of various depression treatments including cognitive behavioral therapy (CBT) and antidepressants SSRI (escitalopram) and SNRI




Fig. 1 Flowchart of the study.

(duloxetine) on the depression-associated metabolites were studied in the PReDICT study. The design of PReDICT study has been published previously [25]. Details on the study and the metabolomics assessments are provided in the Supplementary Materials.

Depression assessment

In the Rotterdam Study, depressive symptoms were assessed with the 20-item version of the Centre for Epidemiologic Studies Depression (CES-D) scale (Supplementary Table 1), a self-report measure of depressive symptoms experienced during the prior week [26]. The total score ranges from 0 to 60, where a higher score indicates more depressive symptoms. In the SHIP-trend and KORA cohorts, depressive symptoms were assessed with the Patient Health Questionnaire 9 (PHQ-9) [27], where each of the nine DSM-IV criteria for depression are scored from 0 to 3. The total score ranges from 0 to 27 where higher score indicates a greater depression severity. In KORA a brief interview version of PHQ-9 called Patient Health Questionnaire Depression (PHQ-D) module was used to measure depression [27, 28]. In the EPIC-Norfolk study depression was assessed using the following question: "Has the doctor ever told you that you have any of the following: depression requiring treatment?" with answers "yes" or "no". In the NEO cohort, depressive symptoms were assessed using the Inventory Depressive Symptomatology Self Report questionnaire (IDS-SR30) [29], which assesses specific depressive symptoms (via a 4-level response system) during the last week and their severity. The total score ranges from 0 to 84, with higher scores indicating higher severity. Thus, in all cohorts except EPIC-Norfolk, depression in participants was measured on a quantitative scale and used as such in the analysis.

In the UKB study, we used the derived lifetime probable major depressive disorder measure as described in Smith et al. [30]. We further defined current depressive symptoms by summing the responses to four questions related to mood in the past two weeks. These include, (1) Over the past two weeks, how often have you felt down, depressed or hopeless?, (2) Over the past two weeks, how often have you had little interest or pleasure in doing things?, (3) Over the past two weeks, how often have you felt tense, fidgety or restless? and (4) Over the past two weeks, how often have you felt tired or had little energy? Answers could be given on a four-point scale ranging from 0 to 3 (0 = not at all, 1 = several days, 2 = more than half of the days and 3 = nearly every day). The total score ranged from 0 to 12 where higher score indicating more severe depression.

In the PReDICT study, participants were treatment-naïve adults defined as having never previously received a minimally adequate course of treatment with an antidepressant medication or evidence-based psychotherapy for a mood disorder, aged 18 to 65 years with moderate-to-severe, non-psychotic MDD depression as assessed by the Structured Clinical Interview for DSM-IV [31] and a psychiatrist's evaluation, and if they scored ≥ 18 on the HRSD17. Eligible patients were randomized equally to one of three 12-week treatment arms: (1) cognitive behavior therapy (CBT, 16 sessions); (2) duloxetine (30–60 mg/d); or (3) escitalopram (10–20 mg/d).

Metabolomics measurements

In all studies, the metabolome was quantified using the Metabolon platform (Metabolon Inc., Durham, USA) (Supplementary Table 1). Different versions of the platform have been used and details on the platforms are included in the Supplementary Materials. In each study, metabolites with

Table 1. Descriptive statistics of the study populations.

	Rotterdam Study	SHIP-trend	KORA	EPIC-Norfolk B2	EPIC-Norfolk B3	NEO
N	484	965	1746	4639	5163	599
Ncases/Ncontrols	-	-	-	638/4001	685/4478	-
Mean age (years) (SD)	73.1 (6.3)	50.1 (13.6)	61 (8.8)	59.9 (8.8)	59.6 (8.9)	55.8 (6.0)
Age range (years)	62–96	20–81	32–77	40–78	40–78	45–66
Females (%)	52.5	56.0	51.4	52.4	52.8	52.6
Mean BMI (kg/m ²) (SD)	26.8 (3.7)	27.4 (4.6)	28.2 (4.8)	26.2 (3.7)	26.2 (3.8)	25.9 (4.0)
Smoking (%)	12.6	22.0	14.5	11.4	10.9	11.9
Medication						
Antidepressants (%)	3.7	4.0	5.6	4.5	3.8	5.3
Lipid-lowering medication (%)	10.5	7.8	16.7	1.4	1.5	7.7
Antihypertensives (%)	0.6	28.2	37.9	19.5	17.0	19.7
Antidiabetics (%)	5.4	0	7.5	1.9	2.0	2.7

≥40% missing values were removed prior to the analysis and for the remaining metabolites, missing metabolite values were replaced with half of the detection limit for that particular metabolite [32]. Subsequently, a natural logarithm transformation was applied to all metabolites and metabolites were scaled to standard deviation units.

In the PRedICT study, metabolites were quantified using targeted metabolomics platforms including ultra-performance liquid chromatography triple quadrupole mass spectrometry (UPLC-TQMS) (Waters XEVO TQ-S, Milford, USA) and gas chromatography time-of-flight mass spectrometry (GC-TOFMS) (Leco Corporation, St Joseph, USA). Metabolites with >20% missing values were excluded. Then, metabolites were log-transformed, imputed and scaled to mean zero and variance 1. Details are provided in the Supplementary Materials.

Non-targeted metabolite detection and quantification was conducted by the metabolomics provider Metabolon, Inc. (Durham, USA) on fasting plasma samples of 10,654 participants from the UK Biobank. The metabolomic dataset measured by Metabolon included 1069 compounds of known structural identity belonging to the following broad categories - amino-acids, peptides, carbohydrates, energy intermediates, lipids, nucleotides, cofactors and vitamins, and xenobiotics. Metabolites data were day-median normalized, and inverse normalized, as the metabolite concentrations were not normally distributed. Metabolites with more than 20% missing values were excluded leaving 722 metabolites of known chemical identity for analysis.

Genotyping

For the GWAS of metabolites, genotyping in the UK Biobank was carried out with a high-density array data (Affymetrix UK Biobank Axiom® Array). Genotypes were subsequently imputed using information from the Human Reference Consortium imputation panel (version r1.1, 2016) [33]. Only individuals of full European ancestry ($N = 8809$) were included in the analyzes in the discovery cohort.

Statistical analyzes

Metabolites association analysis. Linear regression analyzes were used to test the association between the levels of each metabolite (dependent variable) and depression. Three different models were tested, where the first model (model 1) was adjusted for age and sex only, the second model (model 2) was additionally adjusted for antidepressant medication usage, and the third model was an extension of the second model (model 3) with additional adjustment for lipid-lowering medication (yes/no), antihypertensive medication (yes/no), antidiabetic medication (yes/no), BMI (kg/m²), and current smoking (yes/no). The summary statistics from all cohorts were combined in a sample size-weighted meta-analysis using METAL software [34]. Sample size weighted meta-analysis was used since the depression measurement scales were different among cohorts. Only metabolites that were present in two or more studies were included. To investigate the robustness of our findings, a sensitivity analysis was performed by including only cohorts that assessed metabolites with the most recent version of the Metabolon platform (HD4).

Association analysis of major depressive disorder with dietary sources of the depression-associated metabolites in the UK Biobank. Food proxies for the

depression-associated metabolites were identified through the literature. We used logistic regression analysis to test the association between major depressive disorder and dietary sources of metabolites. Age, sex, body mass index (BMI), socio-economic status and principal components (PCs) were used as covariates in the analysis. For the association of current depressive symptoms, we used linear regression analysis. Since vitamin A is fat-soluble and can cross the blood-brain barrier, we performed additional association with white matter hyperintensity (WMH) volume – a measure of brain damage and also associated with MDD – assessed 4–8 years after the baseline assessment. Linear regression analysis was used with the WMH volume as the dependent variable, vitamin supplements (vitamin A, and vitamin D as a negative control) as the independent variable, and age, sex, BMI, head size and principal components as covariates. All analyzes were performed in R.

Metabolites, their food sources and inflammation. Metabolites that were found to be associated with depression were tested for association with C-Reactive protein (CRP) as a measure of inflammation in EPIC-Norfolk, NEO and SHIP-Trend cohorts. CRP was natural log transformed and used as an outcome in a linear regression model adjusted for age and sex, and metabolite level as the independent variable. Further, food sources of metabolites were associated with baseline CRP levels in the UK Biobank cohort in a linear regression analysis adjusted for age, sex, BMI, socio-economic status and PCs.

Metabolite GWAS for Mendelian Randomization (MR) analysis. To test for association between metabolite levels and genotypes, we built linear regression models where the outcome was defined as the transformed level of each metabolite, predicted by the allele dosage at each polymorphic (MAF > 0.01) genotyped or imputed genetic variant. In addition, analyzes were adjusted for age, sex and BMI. All analyzes were conducted using the PLINK software (<https://www.cog-genomics.org/plink/2.0/>).

Mendelian Randomization (MR) analysis. To understand the relationship between the identified metabolites and major depression we performed bidirectional two-sample MR analysis. For major depression we used the independent genome-wide significant single nucleotide polymorphisms (SNPs) reported by Howard et al. [6] as instrumental variables. Summary statistics for these IVs were extracted from Howard et al. The summary statistics for the metabolites were extracted from the GWAS performed in UK Biobank. Of the identified metabolites in this study (model 3), GWAS results were available for six metabolites including 2-aminooctanoate, 10-undecenoate (11:1n1), 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1), hippurate, mannitol/sorbitol and retinol (Supplementary Table 2). The instrumental variables for these six metabolites and their summary statistics were extracted from the same GWAS. Because of scarcity in GWAS-grade significance for SNPs associated with these metabolites, we used independent SNPs that showed the strongest association with a p -value < 10^{-06} as instruments (Supplementary Table 3). The summary statistics for depression for these instrumental variables were extracted from the publicly available dataset (2019 PGC UKB Depression Genome-wide; <https://www.med.unc.edu/pgc/download-results/mdd/>). For the

analysis we used the 'mr_allmethods' option of the R (<https://cran.r-project.org/>) library "MendelianRandomization" [35] that reports the results from the median method (simple, weighted and penalized), Inverse variance weighted and Egger methods (penalized, robust and penalized & robust).

Effect of antidepressant therapy on metabolites in PRedICT study. To examine the strength and significance of metabolite concentration changes within each of the three treatment arms, i.e., (1) CBT (16 sessions); (2) duloxetine (30–60 mg/d); or (3) escitalopram (10–20 mg/d), linear mixed effect models (with random intercept) with metabolite levels (in log scale) as the dependent variable, were fitted while correcting for age, sex, BMI, and baseline HRSD17. Then, the R package "emmeans" was used to compute the least squared means of the contrasts of interest (week 12 vs. baseline) and their corresponding *p*-values.

To detect whether metabolites levels were associated with clinical outcomes, linear regression analyzes corrected for age, sex and treatment arm were performed. Dependent variables (Baseline HRSD17, Week 12 HRSD17, and 12 weeks change in HRSD17) were regressed on either of following independent variables: 1) baseline metabolite, 2) week 12 metabolite, 3) 2 weeks change in metabolites and 4) 12 weeks change in metabolites.

Linking metabolites to human and/or gut metabolism. To assess whether the identified metabolites are products of human metabolism, gut microbial metabolism, or both, we integrated our findings with those of the VMH and Assembly of Gut Organisms through Reconstruction and Analysis (AGORA2) databases. Additional information is provided in the Supplementary Materials.

RESULTS

This study includes 13,596 participants from five independent cohorts including the Rotterdam Study (RS), the Study of Health in Pomerania (SHIP-TREND), the Cooperative Health Research in the Region of Augsburg (KORA) study, the European Prospective Investigation into Cancer (EPIC)-Norfolk Study, and the Netherlands Epidemiology of Obesity (NEO) study. A detailed description of the study participants is provided in Table 1. Depression was measured on a quantitative scale in all cohorts except the EPIC-Norfolk study, where the participants reported depression on a yes/no scale. The mean age ranged from 50.1 years in SHIP-Trend to 73.1 years in the Rotterdam Study. The percentage of female participants (51–56%) and mean body mass index (BMI; between 26–28 kg/m²) were comparable between studies. There were differences in the percentage of smokers between the cohorts, ranging from 11% in EPIC-Norfolk and to 22% in SHIP-Trend.

When testing for an association with depression adjusting for age and sex, 53 (41 novel) metabolites were significantly associated with depression after adjusting for multiple testing (false discovery rate (FDR) < 0.05; Table 2 & Fig. 2). These include nine metabolites in the amino acid metabolism pathway including five previously associated with depression (leucine, kynurenate, citrulline, glutamate and serotonin) [23, 36, 37]. In addition, significant association was found for six carbohydrates (one novel), six cofactors and vitamins, all of which were novel, 26 lipids (25 novel), and six xenobiotics (five novel) (Table 2).

When adjusting for antidepressant use (model 2), 12 metabolites remained significantly associated (FDR < 0.05) with depression (Table 2, Fig. 2), suggesting that most associations observed with depression were confounded by antidepressant medication use. Of the amino acids, only citrulline remained significantly associated with depression after adjustment for antidepressant medication (Table 2, Fig. 2). Other metabolites that remained significantly associated with depression in the extended model included four xenobiotics (4-hydroxycoumarin, hippurate, 3-phenylpropionate (hydrocinnamate) and cinnamoylglycine), four lipids (2-aminooctanoate, 10-undecenoate (11:1n1), 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) and 1-linoleoyl-GPA (18:2)), and three cofactors and vitamins (retinol (vitamin A), bilirubin (Z,Z), bilirubin (E,Z or Z,E)). Among these,

higher levels of 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) and retinol (vitamin A) were associated with an increased risk of depression, while the others were associated with a decreased risk (Fig. 2).

We subsequently build a more conservative model, further adjusting for other medication use, including lipid-lowering medication, antihypertensive medication, antidiabetic medication, BMI and current smoking (model 3). Seven out of the 12 metabolites remained significantly associated with depression (Table 2). These included retinol (vitamin A), hippurate, 4-hydroxycoumarin (coumarol), 2-aminooctanoate (alpha-aminocaprylic acid), 10-undecenoate (11:1n1) (undecylenic acid), 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) (Lecithin), and 1-linoleoyl-GPA (18:2) (lysophosphatidic acid). Additionally, mannitol/sorbitol appeared statistically significant in model 3. Complete results of the meta-analysis are available in Supplementary Table 4.

There was no significant evidence for effect modification by sex (Supplementary Table 5) and the directionality of effects tended to be consistent in men and women. Effect sizes appeared to be stronger in women. Results were consistent across various versions of the Metabolon platform and depression assessing instruments and a sensitivity meta-analysis, which only included results from cohorts that had assessed metabolites on the most recent (HD4) platform, showed that they remained essentially unchanged (Supplementary Table 6).

Association of depression with dietary sources of metabolites in the UK Biobank

For hippurate, fresh fruits and vegetables were identified as the primary source [38]. For 4-hydroxycoumarin vitamin K antagonists were identified as the primary source [39, 40]. For vitamin A/retinol UK Biobank had both vitamin supplement intake and retinol intake from food available. Egg yolk was identified as the primary source of lecithin [41], legumes a proxy for lysophosphatidic acid [42] and artificial sweeteners were identified as the primary source of mannitol/sorbitol [43]. We were unable to identify food proxies for undecylenic acid and alpha-aminocaprylic acid. In a cross-sectional analysis in the UK Biobank, we found a significant positive association of vitamin A intake from supplements with both measures of depression including current depressive symptoms ($\beta = 0.23$, p -value = 1.25×10^{-25}) and lifetime MDD (OR = 1.40, p -value = 9.72×10^{-18}). However, vitamin D supplement intake (negative control) was also significantly positively associated with both measures of depression (Table 3), suggesting that depressed individuals take more vitamin supplements than non-depressed individuals do. Since both vitamin A and vitamin D are fat-soluble and can cross the blood-brain barrier, we performed additional association with the depression-associated brain pathology, i.e., white matter hyperintensity (WMH) volume. Only vitamin A supplement intake was found to be associated with higher volume of WMH ($\beta = 490.49$, p -value = 0.04, Supplementary Table 7), suggesting a possible role of vitamin A in brain damage. To address the issue of reverse causality we observed in case of supplement use, we additionally tested the association of depression with retinol intake estimated from the food consumed in the previous 24 h. Significant positive association of estimated retinol intake was observed with both measures of depression (current depressive symptoms, p -value = 1.26×10^{-08} ; lifetime MDD, p -value = 1.4×10^{-03}). However, the effect estimates were small (Table 3), which may in part be explained by the imprecision of food consumption questionnaires. The primary sources of hippurate, i.e., fresh fruits ($\beta = -0.058$, P -value = 3.29×10^{-191}) and vegetables ($\beta = -0.029$, P -value = 2.11×10^{-82}) intake was significantly reduced in individuals experiencing depressive symptoms at the time of assessment. Further fresh fruits intake was also significantly reduced in individuals who had MDD ($\beta = -0.035$, P -value = 1.42×10^{-19}). Artificial sweetener – source of mannitol/sorbitol – intake was significantly increased in individuals experiencing symptoms of

Table 2. Top findings of the association analysis of metabolites with depression (FDR corrected p -value < 0.05 in model 1).

Chemical ID	Name	Super pathway	Model 1				Model 2				Model 3			
			N	Zscore	Direction ^a	FDR	N	Zscore	Direction ^a	FDR	N	Zscore	Direction ^a	FDR
100001197	10-undecenoate (11:1n1)	Lipid	13,596	-5.12	+----	8.02E-05	13,556	-3.94	+----	1.7E-02	13,549	-3.79	+----	2.71E-02
100001740	mammitol/sorbitol	Carbohydrate	12,631	5.14	+?++++	8.02E-05	12,592	3.39	+?++++	5.02E-02	12,586	3.58	+?++++	4.47E-02
1090	bilirubin (Z,Z)	Cofactors and Vitamins	13,596	-5.33	-----	8.02E-05	13,556	-3.60	-----	3.5E-02	13,549	-2.84	-----	1.83E-01
100001950	bilirubin (E,E) ^a	Cofactors and Vitamins	13,596	-5.25	-----	8.02E-05	13,556	-3.33	-----	5.13E-02	13,549	-2.73	-----	2.08E-01
100002049	4-hydroxycoumarin	Xenobiotics	10,885	-4.99	-?---	1.30E-04	10,847	-4.48	-?---	4.0E-03	10,847	-4.17	-?---	1.12E-02
100008984	1-palmitoyl-2-palmitoleyl-GPC (16:0/16:1) ^a	Lipid	10,885	4.84	+?++++	1.94E-04	10,847	3.58	+?++++	3.5E-02	10,847	3.51	+?++++	4.47E-02
100001951	bilirubin (E,Z or Z,E) ^a	Cofactors and Vitamins	12,631	-4.74	-?---	2.83E-04	12,592	-3.50	-?---	3.5E-02	12,586	-2.98	-?---	1.37E-01
498	retinol (Vitamin A)	Cofactors and Vitamins	10,885	4.65	+?++++	3.58E-04	10,847	3.89	+?++++	1.7E-02	10,847	4.14	+?++++	1.12E-02
100004227	2-aminooctanoate	Lipid	11,850	-4.65	-?---	3.58E-04	11,811	-4.00	-?---	1.7E-02	11,810	-3.92	-?---	1.87E-02
100002253	cinnamoylglycine	Xenobiotics	10,885	-4.40	-?---	9.38E-04	10,847	-3.50	-?---	3.5E-02	10,847	-3.32	-?---	6.71E-02
100000010	3-phenylpropionate (hydrocinnamate)	Xenobiotics	13,596	-4.42	-----	9.38E-04	13,556	-3.73	-----	2.9E-02	13,549	-3.24	-----	7.89E-02
100001251	decanoylcarnitine (C10)	Lipid	13,596	-4.35	+----	1.02E-03	13,556	-3.35	+----	5.13E-02	13,549	-3.15	+----	8.53E-02
1526	1-palmitoyl-2-oleoyl-GPE (16:0/18:1)	Lipid	10,885	4.36	+?++++	1.02E-03	10,847	2.64	-?++++	2.12E-01	10,847	2.44	-?++++	2.68E-01
250	biliverdin	Cofactors and Vitamins	13,596	-4.29	-----	1.24E-03	13,556	-2.88	-----	1.40E-01	13,549	-2.41	-----	2.75E-01
504	serotonin	Amino acid	12,631	-4.24	-?---	1.49E-03	12,592	0.18	-?++++	9.55E-01	12,586	-0.02	-?++++	9.92E-01
192	N-acetylputrescine	Amino acid	10,885	4.06	-?++++	3.01E-03	10,847	2.09	-?++++	3.52E-01	10,847	2.16	-?++++	3.44E-01
100002259	cis-4-decenoylcarnitine (C10:1)	Lipid	13,596	-4.02	-----	3.27E-03	13,556	-2.80	-----	1.58E-01	13,549	-2.47	-----	2.68E-01
212	5-methylthioadenosine (MTA)	Amino acid	10,885	4.03	+?++++	3.27E-03	10,847	2.09	+?++++	3.52E-01	10,847	1.78	+?++++	4.91E-01
100000997	3-hydroxydecanoate	Lipid	11,850	-3.97	+?---	3.89E-03	11,811	-2.60	+?---	2.23E-01	11,810	-2.39	+?---	2.75E-01
1539	1-palmitoyl-2-oleoyl-GPC (16:0/18:1)	Lipid	10,885	3.85	+?++++	6.01E-03	10,847	2.93	+?++++	1.36E-01	10,847	2.76	+?++++	2.03E-01
100000014	hippurate	Xenobiotics	13,596	-3.80	-----	7.10E-03	13,556	-4.17	-----	1.1E-02	13,549	-3.72	-----	2.99E-02
100001392	laurylcarnitine (C12)	Lipid	13,596	-3.73	+----	8.97E-03	13,556	-2.68	+----	1.96E-01	13,549	-2.61	+----	2.48E-01
1128	2-aminobutyrate	Amino acid	13,596	-3.68	-----	9.61E-03	13,556	-2.08	-----	3.54E-01	13,549	-1.84	-----	4.74E-01
561	glutamate	Amino acid	13,596	3.70	+?++++	9.61E-03	13,556	1.92	+?++++	4.13E-01	13,549	1.15	+?++++	7.26E-01
98	kynurenate	Amino acid	10,885	-3.61	-?---	1.22E-02	10,847	-2.79	-?---	1.58E-01	10,847	-2.50	-?---	2.68E-01
100001658	taurithocholate 3-sulfate	Lipid	13,596	-3.52	-----	1.45E-02	13,556	-3.09	-----	9.31E-02	13,549	-3.09	-----	1.01E-01
100001511	1-palmitoleyl-GPC (16:1) ^a	Lipid	13,596	3.54	+?++++	1.45E-02	13,556	2.43	+?++++	2.74E-01	13,549	2.57	+?++++	2.48E-01
100001112	3-hydroxylaurate	Lipid	10,885	-3.53	-?---	1.45E-02	10,847	-2.54	-?---	2.42E-01	10,847	-2.43	-?---	2.69E-01
100008990	1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4) ^a	Lipid	10,885	3.52	-?++++	1.45E-02	10,847	2.22	-?++++	3.00E-01	10,847	2.23	-?++++	3.27E-01
100000773	3-hydroxyoctanoate	Lipid	11,850	-3.54	+?---	1.45E-02	11,811	-2.25	+?---	3.00E-01	11,810	-2.13	+?---	3.63E-01
100001868	4-allylphenol sulfate	Xenobiotics	10,885	-3.48	-?---	1.58E-02	10,847	-2.86	-?---	1.46E-01	10,847	-2.46	-?---	2.68E-01
100001247	octanoylcarnitine (C8)	Lipid	13,596	-3.47	+----	1.58E-02	13,556	-2.62	+----	2.14E-01	13,549	-2.48	+----	2.68E-01

Table 2. continued

Chemical ID	Name	Super pathway	Model 1			Model 2			Model 3					
			N	Zscore	Direction ^a	FDR	N	Zscore	Direction ^a	FDR	N	Zscore	Direction ^a	FDR
100001083	indolepropionate	Amino acid	13,596	-3.48	-----	1.58E-02	13,556	-2.95	-----	1.35E-01	13,549	-2.12	-----	3.66E-01
100001977	beta-cryptoxanthin	Xenobiotics	6246	-3.46	-???	1.60E-02	6208	-3.25	-???	5.74E-02	6208	-2.59	-???	2.48E-01
100006430	arabitol/xylitol	Carbohydrate	12,631	3.44	+?+++++	1.69E-02	12,592	2.48	+?+++++	2.51E-01	12,586	2.69	+?+++++	2.15E-01
100009082	1-linoleoyl-GPA (18:2) ^a	Lipid	10,885	-3.39	-??	1.91E-02	10,847	-3.57	-??	3.5E-02	10,847	-3.53	-??	4.47E-02
100001870	1-palmitoyl-2-linoleoyl-GPE (16:0/18:2)	Lipid	10,885	3.39	+?+++++	1.91E-02	10,847	2.02	+?+++++	3.78E-01	10,847	2.18	+?+++++	3.41E-01
100000257	glucuronate	Carbohydrate	10,885	3.35	+?+++++	2.18E-02	10,847	2.09	+?+++++	3.52E-01	10,847	1.93	+?+++++	4.51E-01
391	citulline	Amino acid	13,596	-3.31	-----	2.45E-02	13,556	-3.53	-----	3.5E-02	13,549	-3.29	-----	7.22E-02
100001121	pyridoxate	Cofactors and Vitamins	13,596	3.29	+?+++++	2.50E-02	13,556	2.71	+?+++++	1.83E-01	13,549	3.17	+?+++++	8.53E-02
100002021	5alpha-androstan-3beta,17alpha-diol disulfate	Lipid	10,885	-3.25	-??	2.79E-02	10,847	-2.05	-??	3.67E-01	10,847	-1.63	-??	5.35E-01
100001287	epiandrosterone sulfate	Lipid	13,596	-3.16	+?+++++	3.59E-02	13,556	-1.71	+?+++++	4.70E-01	13,549	-1.73	+?+++++	5.03E-01
100008914	1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6)	Lipid	10,885	3.13	-??+++++	3.89E-02	10,847	2.92	-??+++++	1.36E-01	10,847	2.94	-??+++++	1.52E-01
100001320	erythronate ^a	Carbohydrate	12,631	3.12	+?+++++	3.89E-02	12,592	1.76	+?+++++	4.55E-01	12,586	1.77	+?+++++	4.91E-01
935	sucrose	Carbohydrate	10,885	3.13	+?+++++	3.89E-02	10,847	1.61	+?+++++	4.99E-01	10,847	1.16	+?+++++	7.21E-01
100001567	1-palmitoyl-GPE (16:0)	Lipid	13,596	3.10	+?+++++	4.01E-02	13,556	2.15	+?+++++	3.28E-01	13,549	2.57	+?+++++	2.48E-01
100008991	1-palmitoyl-2-docosahexaenoyl-GPE (16:0/22:6)	Lipid	10,401	3.06	???	4.26E-02	10,401	2.43	???	2.74E-01	10,401	2.71	???	2.15E-01
100001657	glycolithocholate sulfate ^a	Lipid	11,850	-3.06	-??	4.26E-02	11,811	-2.46	-??	2.60E-01	11,810	-2.29	-??	3.09E-01
100008977	1-stearoyl-2-arachidonoyl-GPE (18:0/20:4)	Lipid	10,885	3.07	-??+++++	4.26E-02	10,847	1.94	-??+++++	4.07E-01	10,847	1.93	-??+++++	4.51E-01
823	pyruvate	Carbohydrate	13,596	3.06	+?+++++	4.26E-02	13,556	2.28	+?+++++	2.91E-01	13,549	1.84	+?+++++	4.74E-01
397	leucine	Amino acid	13,596	-3.04	-----	4.44E-02	13,556	-2.73	-----	1.76E-01	13,549	-3.33	-----	6.71E-02
100002945	15-methylpalmitate	Lipid	13,596	-3.04	+?+++++	4.44E-02	13,556	-2.77	+?+++++	1.63E-01	13,549	-2.40	+?+++++	2.75E-01
100009066	1-palmitoyl-2-oleoyl-GPI (16:0/18:1) ^a	Lipid	6246	3.03	+?+++++	4.50E-02	6208	1.96	+?+++++	4.01E-01	6208	1.86	+?+++++	4.66E-01

^aThe order of the direction column: Rotterdam Study, SHIP-trend, KORa, EPIC-Norfolk B2, EPIC-Norfolk B3, NEO.




Fig. 2 Results of Metabolome-wide association analysis. This plot shows the top findings of the association analysis of metabolites with depressive symptoms, for all three models tested. Only metabolites with FDR p -value < 0.1 are shown in this Figure. The associations with a negative Z-score are depicted in gray, while the positive associations are depicted in orange. The plot is divided per metabolite subgroup. Significance levels: **:FDR < 0.001 , *:FDR < 0.05 . Script for Figure modified from Nath et al. [100].

depression ($\beta = 0.165$, P -value = 2.8×10^{-21}) and those with MDD ($\beta = 0.193$, P -value = 3.65×10^{-16}). Intake of legumes (source of lysophosphatidic acid) was inversely associated with current depressive symptoms ($\beta = -0.063$, P -value = 0.03) and positively associated with lifetime MDD ($\beta = 0.108$, P -value = 0.008). Moreover, consumption of eggs – a source of lecithin – was increased both in individuals experiencing symptoms of depression at the time of assessment ($\beta = 0.05$, P -value = 0.001) and lifetime MDD ($\beta = 0.05$, P -value = 0.018). Use of vitamin K antagonists, a proxy for 4-hydroxycoumarin, was positively associated with current depressive symptoms ($\beta = 0.43$, p -value = 1.04×10^{-46}) but not with lifetime MDD (Table 3).

Metabolites, their food sources and inflammation. Consistent with the association of depression, levels of hippurate ($\beta = -0.09$, P -value = 0), alpha-aminocaproic acid ($\beta = -0.08$, P -value = 2.5×10^{-12}), lysophosphatidic acid ($\beta = -0.15$, P -value = 0) and 4-hydroxycoumarin ($\beta = -0.09$, P -value = 3.3×10^{-16}) were all significantly associated with reduced levels of CRP (Supplementary Table 8). Retinol levels were associated with reduced levels of CRP ($\beta = -0.07$, P -value = 3.3×10^{-10}). Further food sources of hippurate, retinol, lysophosphatidic acid, mannitol/sorbitol and lecithin including fresh fruits ($\beta = -0.04$, P -value = 0), vegetables ($\beta = -0.02$, P -value = 1.2×10^{-199}), retinol intake from food ($\beta = 6.0 \times 10^{-05}$, P -value = 6.7×10^{-04}), eggs ($\beta = 0.04$, P -value = 7.9×10^{-07}) and artificial sweetener use ($\beta = 0.02$, P -value =

0.012) were all significantly associated with CRP and consistent with the findings of depression (Supplementary Table 9).

Mendelian randomization analysis

Testing the hypothesis that major depression results in changes of circulating metabolites in the Mendelian randomization analysis (MR), nominally significant results were obtained for 2-aminooctanoate and 10-undecenoate (11:1n1), under the MR-Egger method and weighted median method, respectively. However, these findings did not remain significant after adjustment for multiple testing (Supplementary Table 10). MR models in which we tested the hypothesis that levels of circulating metabolites increase the risk of depression provided significant evidence for a causal relation between hippurate and the risk of depression, both in the MR-Egger robust and penalized-robust methods (Supplementary Table 11). The effect estimate was consistent with the inverse relationship observed between hippurate and major depression in this study. However, a significant intercept was also observed suggesting pleiotropy. To exclude a pleiotropic effect, we studied the effect of intervention on the metabolite in the PReDICT trial.

Effect of antidepressant therapy on hippurate

To further evaluate the impact of antidepressant therapy including cognitive behavioral therapy (CBT), duloxetine – a serotonin-norepinephrine reuptake inhibitor (SNRI) and escitalopram – a

Table 3. Results of association of depression outcomes with dietary sources of metabolites in the UK Biobank.

Metabolite	Food Proxy	Current depressive symptoms			Lifetime MDD				
		Beta	SE	P-value	N	Beta	SE	P-value	N
Retinol	Vitamin A supplements	0.243928	0.022056	2.00E-28	303,274	0.351808	0.039820	1.00E-18	189,118
Retinol	Retinol intake from food	0.000227	0.000040	1.12E-08	61,201	0.000170	0.000055	2.14E-03	38,648
Negative Control	Vitamin D supplements	0.236158	0.015930	1.05E-49	311,932	0.370265	0.028033	7.87E-40	193,957
Hippurate	Fresh Fruits	-0.058028	0.001966	3.29E-191	433,153	-0.035044	0.003872	1.42E-19	263,822
Hippurate	Raw Vegetables	-0.028271	0.001470	2.11E-82	430,354	0.004597	0.002687	8.71E-02	261,767
4-hydroxycoumarin	Vitamin K antagonists	0.315052	0.029455	1.07E-26	434,232	0.054569	0.057843	3.45E-01	264,658
mannitol/sorbitol	Artificial sweetener	0.164990	0.017416	2.80E-21	63,079	0.193453	0.023738	3.65E-16	39,829
1-linoleoyl-GPA (18:2)	Legumes	-0.063329	0.029184	3.00E-02	63,079	0.107547	0.040704	8.24E-03	39,829
1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1)	Eggs	0.049938	0.015835	1.61E-03	63,079	0.052034	0.021952	1.78E-02	39,829

selective serotonin reuptake inhibitor (SSRI) on hippurate we consulted the PRoDICT study. The PRoDICT study allows us to test the effect of antidepressant therapy on the metabolite levels in circulation by measuring the metabolite levels before and after the antidepressant therapy. In PRoDICT, we found that levels of hippurate in the circulation increased significantly from baseline to week 12 only after treatment with escitalopram (estimated week 12 vs. baseline difference = 0.45, 95% confidence interval (CI; 0.16,0.74), p -value = 0.002; Supplementary Fig. 1), but not in the cognitive behavior therapy (CBT) and duloxetine treatment arms (CBT: estimated difference = -0.02, 95% CI (-0.39,0.33) and p -value = 0.87; duloxetine: estimated difference = 0.13, 95% CI (-0.17,0.44) and p -value = 0.38). In this study, we could not show a relation between hippurate and depression as the study recruited patients only and lacked healthy controls. In patients receiving pharmacotherapy (escitalopram and duloxetine arms), the association of baseline depression as measured by the 17-item Hamilton Rating Scale for Depression (HRSD17) and baseline hippurate was not statistically significant (beta = 0.04, 95% CI (-0.03,0.11), p -value = 0.27). Further, no significant association was observed between depression in week 12 as measured by the HRSD17 and week 12 hippurate (beta = 0.09, p -value = 0.45) and 12 weeks change in HRSD17 and 12 weeks change in hippurate (beta = 0.02, 95% CI (-0.65, 1.57), p -value = 0.85).

Linking the human circulating metabolome to gut microbiome metabolism

Of the 53 metabolites identified in this study in model 1, 28 metabolites could be matched to a unique VMH metabolite ID. For each metabolite, the presence or absence in the global human reconstruction, Recon3D [44], and a resource of 7206 reconstructions of human gut microbes, AGORA2 (<https://www.biorxiv.org/content/10.1101/2020.11.09.375451v1>) was retrieved. In total, 12 metabolites were present in both the human and gut microbial metabolic networks, three were only present in gut microbes, and 13 were only present in human (Supplementary Table 12). To further investigate potential links between the microbiome and metabolites associated with depression, the potential of the 7206 AGORA2 strains to consume or secrete the 15 microbial metabolites identified in this study was computed. Since hippurate is synthesized in the liver and renal cortex from the microbial metabolite benzoate [45], the uptake and secretion potential for benzoate was also predicted for the 7206 strains.

A wide range of genera and species were involved in the uptake of mannitol (Supplementary Table 13, Supplementary Fig. 2). Mannitol is largely secreted by several species of the genus *Bacteroides* followed by *Lactobacillus*, among others (Supplementary Table 13). Both genera have previously been found to be associated with depression [46]. In total, 3616 AGORA2 strains mainly of the Gammaproteobacteria and Bacilli classes (Supplementary Table 14, Supplementary Fig. 2) synthesized benzoate as a product of benzamide (VMH reaction ID: BZAMAH). Interestingly, benzamides are a class of antipsychotic medication.

DISCUSSION

In this study, we identified novel associations with depression for six metabolites, including retinol (vitamin A), 4-hydroxycoumarin, 2-aminooctanoate, 10-undecenoate (11:1n1), 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1), 1-linoleoyl-GPA (18:2) and confirmed the association of hippurate and mannitol/sorbitol. We found that the relation of hippurate and depression may be causal and that hippurate levels can be modified by a specific antidepressant, escitalopram. Further, consistent with the association of the metabolites with depression, the consumption of dietary sources of hippurate and 1-linoleoyl-GPA (18:2) including fresh fruits, vegetables and legumes was significantly reduced in individuals with higher depressive symptoms, and associated with significantly

decreased levels of CRP. In addition, the consumption of dietary sources of retinol, mannitol/sorbitol and 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) including retinol score estimated from diet, artificial sweeteners and eggs was significantly increased in individuals with higher depressive symptoms and associated with increased blood levels of CRP.

One of the most interesting findings of this study is the identification of the association of higher levels of retinol (active form of vitamin A) with depression. There have been several case reports of individuals with vitamin A intoxication with no previous history of depression, who developed symptoms of depression and even psychosis when overdosed with vitamin A [47, 48]. Depressive symptoms resolved upon discontinuation of vitamin A, implying that depression may be a side effect of vitamin A intake [47]. Animal models have suggested elevated monoamine oxidase enzyme activity and depression-related behavior upon vitamin A supplementation [49, 50]. Our study is the first to link higher levels of retinol in blood with depression in the general population. Retinol and its derivatives known as retinoids are lipid soluble and can cross the blood-brain barrier. Vitamin A is required for brain development and functioning [51, 52]. However, excess of vitamin A is neurotoxic and may result in brain shrinkage [52]. Brain areas high in retinoic acid signaling and receptors overlap with areas of relevance to stress and depression [53]. Further, vitamin A is known to increase the synthesis of triglyceride-rich very low-density lipoproteins (VLDLs) and apolipoproteins in the serum [54, 55], which we found associated with depression in our previous study [21]. Since food is the primary source of vitamin A, an important question to answer is whether vitamin A intake is associated to depression. In the UK Biobank, we found significant increase in dietary retinol intake in individuals with depression. Thus, our findings ask for intervention studies that evaluate prospectively the effect of vitamin A reduction in depressed patients.

Two of the most strongly associated metabolites with depression were xenobiotics, hippurate and 4-hydroxycoumarin. In line with the findings of our study, decreased urine and plasma levels of hippurate have consistently been associated with unipolar and bipolar depression in several studies and it has been suggested as a biomarker for depressive disorders [23]. Our MR analysis suggests that low hippurate levels in circulation are a part of the causal pathway leading to depression. However, as the MR could not exclude a pleiotropic effect, our findings yield a hypothesis that requires further evaluation in a clinical trial. While we could not show an association between hippurate and depression in the PRoDICT study, as the study lacked healthy controls, hippurate levels were higher 12 weeks after initiation of SSRI therapy (escitalopram) but not for SNRI or CBT, raising the question whether blood levels of hippurate can be used in clinical trials for compliance and efficacy of SSRIs specifically. Hippurate is derived from benzoate and polyphenols and is reported to be a metabolomic marker of gut microbiome diversity [38], fruits and vegetables intake [56], diet quality [57] and metabolic health [58]. In line with the decreased levels of hippurate in depressed individuals found in our metabolome-wide association analysis, we found significantly decreased fresh fruit intake among individuals with depression in the UKB, which is consistent with the findings of the previous studies that high consumption of fruits, vegetables, nuts, and legumes is associated with a reduced risk of depression [8, 59]. Further, both hippurate and its food sources including fresh fruits and vegetables were associated with significantly reduced inflammation in our study, which is in line with the findings of the previous clinical trials [60]. We hypothesize that this reduction is mediated through hippurate, which requires evaluation in future studies.

The metabolite 4-hydroxycoumarin is a fungal derivative of coumarin. Coumarins are found naturally in plants and spices [61] and coumarin is converted into 4-hydroxycoumarin by fungi [39].

4-hydroxycoumarin is then converted into dicoumarol in the presence of formaldehyde [39]. Dicoumarol is an anticoagulant (warfarin) that inhibits the synthesis of vitamin K, also called vitamin K antagonist, and is commonly used to treat thromboembolic diseases [40]. In the UKB, we found significant positive association of anticoagulant use (vitamin K antagonists) with major depression. A history of depression is a risk factor for thromboembolism [62–64]. Antidepressants are also known to interact with warfarin [65] and are also associated with increased risk of thromboembolism [66]. Taking all findings together, we hypothesize that depression/antidepressant use depletes 4-hydroxycoumarin in circulation leading to thromboembolism. Vitamin K has been shown to act in the nervous system as it is involved in sphingolipid synthesis [67]. Sphingolipids are present in high concentrations in cell membranes of neuronal and glial cells [68]. Sphingolipids are essential for important cellular events, including proliferation, differentiation, senescence, cell-cell interactions, and transformation [69] and they have been linked to aging, Alzheimer's disease, and Parkinson's disease [70–72]. Further, sphingolipids were found to play a crucial role in the development of depression- and anxiety-related behaviors in mice [73, 74] and depression is seen often in patients with sphingolipid storage diseases [75–79]. Treatment with escitalopram /citalopram is also associated with changes in sphingolipids [80]. In our study, we did not find an association of depression with circulating sphingolipids present on the Metabolon platform. However, we cannot exclude that 4-hydroxycoumarin in the blood affects sphingolipid metabolism in the brain specifically.

Other metabolites that were found to be significant in our study include mannitol/sorbitol, of which increased levels were associated with depression. Higher levels of sorbitol in plasma and urine have previously been consistently reported in patients with unipolar and bipolar depression and, like hippurate, it has been suggested as a diagnostic biomarker of depression [23]. Mannitol/sorbitol are sugar alcohols found in food such as fruits and berries and often used in diet/sugar free foods as sweeteners [81]. Fructose reduced diets have been shown to improve gastrointestinal disorders, depression and mood disorders [82]. Our AGORA2 analysis suggests that mannitol is mainly secreted by several species of *Bacteroides*, *Lactobacillus*, *Fructobacillus*, *Alistipes* and *Bifidobacterium*. Interestingly, all genera, except for *Fructobacillus* have previously been associated with depression [46], asking for further studies on the role of the microbiome, circulating levels of mannitol and depression.

Finally, there were four lipids identified in our study (2-aminooctanoate, 10-undecenoate (11:1n1), 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) and 1-linoleoyl-GPA (18:2)) significantly associated with depression. 1-Palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) also known as phosphatidylcholine (16:0/16:1) or lecithin is commonly found in foods like egg yolk and soybean, and is a precursor of choline. Lecithin is believed to cause depression by increasing the production of acetylcholine in the brain [83]. When fed to animals and humans, lecithin significantly increases the levels of choline in blood and brain and of acetylcholine in brain [84–86]. Our study is the first to show higher circulating levels of lecithin in the depressed individuals from the general population. The other three lipids 2-aminooctanoate, 10-undecenoate (11:1n1) and 1-linoleoyl-GPA (18:2) were negatively associated with depression. 2-Aminooctanoate (alpha-aminocaproic acid) and 10-undecenoate (11:1n1) (undecylenic acid) are neutral hydrophobic molecules for which there is not much known in the literature. Lower levels of 10-undecenoate (11:1n1) have been found in individuals with non-alcoholic fatty liver disease [87]. 1-linoleoyl-GPA (18:2) is a lysophosphatidic acid (LPA 18:2). LPA is a bioactive membrane lipid that acts on at least six distinct G protein-coupled receptors (LPA₁₋₆) and plays a role in pain sensitivity and emotional regulation [88]. LPA knock out mice exhibit anxiety-related behaviour [88, 89].

We found that decreased plasma levels of serotonin, kynurenate, leucine and citrulline and higher levels of glutamate were associated with depression. Lower plasma/serum levels of serotonin, kynurenate, citrulline and leucine and higher levels of glutamate have been reported in relationship to depression in earlier studies [23, 36, 37, 90], which also appears consistent with our findings of model 1. However, we and others have shown that antidepressants affect plasma/serum levels of serotonin, glutamate, leucine and kynurenine [91–94]. An important finding of our study is that only citrulline remained significantly associated with depression after adjusting for antidepressant medication use, suggesting the other metabolites change as a result from the medication. Lower levels of citrulline and its precursor arginine were previously associated to depression in unmedicated individuals [37, 95]. Interestingly, treatment with SSRIs significantly increase the levels of plasma citrulline [80]. Further, levels of plasma citrulline were found to be significantly increased two hours post treatment with ketamine, suggesting a possible mechanism of action of the rapid acting drug [96]. Citrulline is an intermediate in the urea cycle and linked to nitric-oxide synthesis [97]. It is absorbed by the gut and has useful therapeutic effects against cardiovascular diseases [98]. In our study the association of citrulline with depression lost its significance, albeit not completely, after adjusting for cardiovascular medication use and BMI.

Our study is the first large-scale effort combining metabolites measured on assorted, untargeted metabolomics platforms (Metabolon) studied in relationship to depression. In addition to confirming several previously identified metabolites in smaller studies, we successfully identified novel metabolites that are associated with depression. Our findings are robust across different versions of the Metabolon platform or the criteria assessing presence of clinical or subclinical depression. A possible limitation of our study is that we have meta-analyzed summary statistics from multiple cohorts that are different in their baseline characteristics including age. Depression in old age is considered to have a different pathogenesis compared to depression in younger individuals. Further, there are differences in metabolomics platform versions and instruments that were used by different cohorts to assess depression, all of which have a negative impact on the statistical power of the study. Older versions of the Metabolon platform reported significantly fewer known metabolites compared to the more recent implementations. Another limitation of our study is the presence of residual confounding. Despite adjusting for most known confounders including medication use and the lifestyle factors smoking and BMI, confounding may still be present and may influence the results [99]. Further, our MR analysis was most likely underpowered lacking strong instrumental variables for the associated metabolites.

Analysing circulating levels of 806 metabolites from untargeted metabolomics platforms in 13,596 individuals, we identified six new associations of metabolites with depression including retinol (vitamin A), 4-hydroxycoumarin and four lipids, 2-aminooctanoate, 10-undecenoate (11:1n1), 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) and 1-linoleoyl-GPA (18:2), while confirming known associations of hippurate and mannitol/sorbitol. We further show that previously identified associations of depression with metabolites belonging to the amino-acid pathways including serotonin, kynurenate, leucine and glutamate are likely explained by antidepressant medication. Our findings point to effective preventive targets, as most of these metabolites are food derived and thus can be altered in patients by modifying diet.

Data Sharing

The datasets generated during and/or analyzed during the current study are not publicly available due to restrictions based on privacy regulations and informed consent of the participants. All

summary statistics are provided in the Supplementary Material. For individual cohort level data, respective Principal Investigators can be contacted. For the Rotterdam Study data, requests should be directed towards the management team of the Rotterdam Study (secretariat.epi@erasmusmc.nl), which has a protocol for approving data requests.

The EPIC-Norfolk data can be requested by bona fide researchers for specified scientific purposes via the study website (<https://www.mrc-epid.cam.ac.uk/research/studies/epic-norfolk/>). Data will either be shared through an institutional data sharing agreement or arrangements will be made for analyses to be conducted remotely without the need for data transfer.

REFERENCES

- Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. Cross-national epidemiology of DSM-IV major depressive episode. *BMC Med*. 2011;9:90.
- Salari N, Hosseini-Far A, Jalali R, Vaisi-Raygani A, Rasoulopoor S, Mohammadi M, et al. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis. *Glob Health*. 2020;16:57.
- Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. *Mol Psychiatry*. 2022. <https://doi.org/10.1038/s41380-022-01661-0>.
- Pigott HE, Leventhal AM, Alter GS, Boren JJ. Efficacy and Effectiveness of Antidepressants: current Status of Research. *Psychother Psychosom*. 2010;79:267–79.
- Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. *Am J Psychiatry*. 2000;157:1552–62.
- Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shiri M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nat Neurosci*. 2019;22:343–52.
- Batterham PJ, Christensen H, Mackinnon AJ. Modifiable risk factors predicting major depressive disorder at four year follow-up: a decision tree approach. *Bmc Psychiatry*. 2009;9:75.
- Firth J, Gangwisch JE, Borisini A, Wootton RE, Mayer EA. Food and mood: how do diet and nutrition affect mental wellbeing? *BMJ*. 2020;369:m2382.
- Ghosh TS, Rampelli S, Jeffery IB, Santoro A, Neto M, Capri M, et al. Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries. *Gut*. 2020;69:1218–28.
- Li Y, Lv MR, Wei YJ, Sun L, Zhang JX, Zhang HG, et al. Dietary patterns and depression risk: a meta-analysis. *Psychiatry Res*. 2017;253:373–82.
- Firth J, Marx W, Dash S, Carney R, Teasdale SB, Solmi M, et al. The effects of dietary improvement on symptoms of depression and anxiety: a meta-analysis of randomized controlled trials. *Psychosom Med*. 2019;81:265–80.
- Lichtenstein AH, Appel LJ, Vadiveloo M, Hu FB, Kris-Etherton PM, Rebholz CM, et al. 2021 dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association. *Circulation*. 2021;144:e472–e87.
- Abbate M, Gallardo-Alfaro L, Bibiloni MDM, Tur JA. Efficacy of dietary intervention or in combination with exercise on primary prevention of cardiovascular disease: a systematic review. *Nutr Metab Cardiovasc Dis*. 2020;30:1080–93.
- Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to mediterranean diet and health status: meta-analysis. *BMJ*. 2008;337:a1344.
- Kang HJ, Kim SY, Bae KY, Kim SW, Shin IS, Yoon JS, et al. Comorbidity of depression with physical disorders: research and clinical implications. *Chonnam Med J*. 2015;51:8–18.
- Sethi S, Brietzke E. Omics-based biomarkers: application of metabolomics in neuropsychiatric disorders. *Int J Neuropsychopharmacol*. 2015;19:pyv096.
- Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. *Neurobiol Dis*. 2009;35:165–76.
- Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. *Nat Rev Mol Cell Biol*. 2012;13:263–9.
- Valles-Colomer M, Falony G, Darzi Y, Tigchelaar EF, Wang J, Tito RY, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. *Nat Microbiol*. 2019;4:623–32.
- Liu J, Lahousse L, Nivard MG, Bot M, Chen L, van Klinken JB, et al. Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas. *Nat Med*. 2020;26:110–7.
- Bot M, Milaneschi Y, Al-Shehri T, Amin N, Garmaeva S, Onderwater GLJ, et al. Metabolomics profile in depression: a pooled analysis of 230 metabolic markers in 5283 cases with depression and 10,145 controls. *Biol Psychiatry*. 2020;87:409–18.

22. Amin N, Liu J, Bonnechere B, MahmoudianDehkordi S, Arnold M, Batra R, et al. Interplay of metabolome and gut microbiome in individuals with major depressive disorder vs control individuals. *JAMA Psychiatry*. 2023;80:597–609.
23. MacDonald K, Krishnan A, Cervenka E, Hu G, Guadagno E, Trakadis Y. Biomarkers for major depressive and bipolar disorders using metabolomics: a systematic review. *Am J Med Genet B*. 2019;180:122–37.
24. Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J, et al. An atlas of genetic influences on human blood metabolites. *Nat Genet*. 2014;46:543–50.
25. Dunlop BW, Binder EB, Cubells JF, Goodman MM, Kelley ME, Kinkead B, et al. Predictors of remission in depression to individual and combined treatments (PREdict): study protocol for a randomized controlled trial. *Trials*. 2012;13:106.
26. Lewinsohn PM, Seeley JR, Roberts RE, Allen NB. Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. *Psychol Aging*. 1997;12:277–87.
27. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16:606–13.
28. Berth H, Löwe B, Spitzer RL, Zipfel S, Herzog W. PHQ-D. Gesundheitsfragebogen für Patienten. *Zeitschrift für Medizinische Psychologie*. 2003;12:90–93.
29. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. *Psychol Med*. 1996;26:477–86.
30. Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J, et al. Prevalence and characteristics of probable major depression and bipolar disorder within UK biobank: cross-sectional study of 172,751 participants. *PLoS One*. 2013;8:e75362.
31. First MB, Spitzer RL, Gibbon M, Williams JB. Structured clinical interview for the DSM-IV Axis Disorders (SCID PTSD Module). In: *Biometrics Research Department NSPI*. New York 1996.
32. MahmoudianDehkordi S, Arnold M, Nho K, Ahmad S, Jia W, Xie G, et al. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome. *Alzheimers Dement*. 2019;15:76–92.
33. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet*. 2016;48:1279–83.
34. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genome-wide association scans. *Bioinformatics*. 2010;26:2190–1.
35. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. *Int J Epidemiol*. 2017;46:1734–9.
36. Bakkaloglu B, Yabanoglu S, Ozyuksel BR, Uaar G, Ertugrul A, Demir B, et al. Platelet and plasma serotonin levels and platelet monoamine oxidase activity in patients with major depression: effects of sertraline treatment. *Turk J Biochem*. 2008;33:97–103.
37. Hess S, Baker G, Gyenes G, Tsuyuki R, Newman S, Le Melleo JM. Decreased serum L-arginine and L-citrulline levels in major depression. *Psychopharmacology (Berl)*. 2017;234:3241–7.
38. Pallister T, Jackson MA, Martin TC, Zierer J, Jennings A, Mohnhey RP, et al. Hippurate as a metabolomic marker of gut microbiome diversity: modulation by diet and relationship to metabolic syndrome. *Sci Rep*. 2017;7:13670.
39. Liu B, Raeth T, Beuerle T, Beerhues L. A novel 4-hydroxycoumarin biosynthetic pathway. *Plant Mol Biol*. 2010;72:17–25.
40. Manolov I, Maichle-Moessmer C, Danchev N. Synthesis, structure, toxicological and pharmacological investigations of 4-hydroxycoumarin derivatives. *Eur J Med Chem*. 2006;41:882–90.
41. Alhaji MJ, Montero N, Yarce CJ, Salamanca CH. Lecithins from vegetable, land, and marine animal sources and their potential applications for cosmetic, food, and pharmaceutical sectors. *Cosmetics*. 2020;7:87.
42. Lee BH, Choi SH, Kim HJ, Jung SW, Kim HK, Nah SY. Plant lysophosphatidic acids: a rich source for bioactive lysophosphatidic acids and their pharmacological applications. *Biol Pharm Bull*. 2016;39:156–62.
43. Zumbe A, Lee A, Storey D. Polyols in confectionery: the route to sugar-free, reduced sugar and reduced calorie confectionery. *Br J Nutr*. 2001;85:531–45.
44. Brunk E, Sahoo S, Zielinski DC, Altunkaya A, Drager A, Mih N, et al. Recon3D enables a three-dimensional view of gene variation in human metabolism. *Nat Biotechnol*. 2018;36:272–81.
45. Lees HJ, Swann JR, Wilson ID, Nicholson JK, Holmes E. Hippurate: the natural history of a mammalian-microbial cometabolite. *J Proteome Res*. 2013;12:1527–46.
46. Cheung SG, Goldenthal AR, Uhlemann AC, Mann JJ, Miller JM, Sublette ME. Systematic review of gut microbiota and major depression. *Front Psychiatry*. 2019;10:34.
47. Bremner JD, Shearer KD, McCaffery PJ. Retinoic acid and affective disorders: the evidence for an association. *J Clin Psychiatry*. 2012;73:37–50.
48. Landy D. Pibloktoq (hysteria) and Inuit nutrition: possible implication of hypervitaminosis A. *Soc Sci Med*. 1985;21:173–85.
49. O'Reilly K, Bailey SJ, Lane MA. Retinoid-mediated regulation of mood: possible cellular mechanisms. *Exp Biol Med (Maywood)*. 2008;233:251–8.
50. de Oliveira MR, da Rocha RF, Pasquali MA, Moreira JC. The effects of vitamin A supplementation for 3 months on adult rat nigrostriatal axis: increased monoamine oxidase enzyme activity, mitochondrial redox dysfunction, increased beta-amyloid(1-40) peptide and TNF-alpha contents, and susceptibility of mitochondria to an in vitro H2O2 challenge. *Brain Res Bull*. 2012;87:432–44.
51. Lane MA, Bailey SJ. Role of retinoid signalling in the adult brain. *Prog Neurobiol*. 2005;75:275–93.
52. Mey J, McCaffery P. Retinoic acid signaling in the nervous system of adult vertebrates. *Neuroscientist*. 2004;10:409–21.
53. Bremner JD, McCaffery P. The neurobiology of retinoic acid in affective disorders. *Prog Neuropsychopharmacol Biol Psychiatry*. 2008;32:315–31.
54. Gerber LE, Erdman JW Jr. Changes in lipid metabolism during retinoid administration. *J Am Acad Dermatol*. 1982;6:664–74.
55. Klor HU, Weizel A, Augustin M, Diepgen TL, Elsner P, Homey B, et al. The impact of oral vitamin A derivatives on lipid metabolism - what recommendations can be derived for dealing with this issue in the daily dermatological practice? *J Dtsch Dermatol Ges*. 2011;9:600–6.
56. Guerra A, Folesani G, Mena P, Ticinesi A, Allegri F, Nouvenne A, et al. Hippuric acid in 24 h urine collections as a biomarker of fruits and vegetables intake in kidney stone formers. *Int J Food Sci Nutr*. 2014;65:1033–8.
57. Stratakis N, Siskos AP, Papadopoulou E, Nguyen AN, Zhao Y, Margetaki K, et al. Urinary metabolic biomarkers of diet quality in European children are associated with metabolic health. *Elife*. 2022;11:e71332.
58. Brial F, Chilloux J, Nielsen T, Vieira-Silva S, Falony G, Andrikopoulos P, et al. Human and preclinical studies of the host-gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health. *Gut*. 2021;70:2105–14.
59. Lassale C, Batty GD, Baghhdadi A, Jacka F, Sanchez-Villegas A, Kivimaki M, et al. Healthy dietary indices and risk of depressive outcomes: a systematic review and meta-analysis of observational studies. *Mol Psychiatry*. 2019;24:965–86.
60. Hosseini B, Berthon BS, Saedisomeolia A, Starkey MR, Collison A, Wark PAB, et al. Effects of fruit and vegetable consumption on inflammatory biomarkers and immune cell populations: a systematic literature review and meta-analysis. *Am J Clin Nutr*. 2018;108:136–55.
61. Lončar M, Jakovljević M, Šubarić D, Pavlić M, Buzjak Služek V, Cindrić I, et al. Coumarins in Food and Methods of Their Determination. *Foods*. 2020;9:645.
62. von Kanel R, Margani A, Stauber S, Meyer FA, Demarmels Biasiutti F, Vokt F, et al. Depressive symptoms as a novel risk factor for recurrent venous thromboembolism: a longitudinal observational study in patients referred for thrombophilia investigation. *PLoS One*. 2015;10:e0125858.
63. Kunutsor SK, Seidu S, Khunti K. Depression, antidepressant use, and risk of venous thromboembolism: systematic review and meta-analysis of published observational evidence. *Ann Med*. 2018;50:529–37.
64. Lee CW, Liao CH, Lin CL, Liang JA, Sung FC, Kao CH. Depression and risk of venous thromboembolism: a population-based retrospective cohort study. *Psychosom Med*. 2015;77:591–8.
65. Sansone RA, Sansone LA. Warfarin and Antidepressants: happiness without Hemorrhaging. *Psychiatry (Edgmont)*. 2009;6:24–9.
66. Parkin L, Balkwill A, Sweetland S, Reeves GK, Green J, Beral V, et al. Antidepressants, depression, and venous thromboembolism risk: large prospective study of UK women. *J Am Heart Assoc*. 2017;6:e005316.
67. Ferland G. Vitamin K and the nervous system: an overview of its actions. *Adv Nutr*. 2012;3:204–12.
68. Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and function. *J Lipid Res*. 2009;50:591–6.
69. Zeidan YH, Hannun YA. Translational aspects of sphingolipid metabolism. *Trends Mol Med*. 2007;13:327–36.
70. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. *Proc Natl Acad Sci USA*. 2004;101:2070–5.
71. Jana A, Hogan EL, Pahan K. Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death. *J Neurol Sci*. 2009;278:5–15.
72. Posse de Chaves E, Sipione S. Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction. *FEBS Lett*. 2010;584:1748–59.
73. Gulbins E, Palmada M, Reichel M, Luth A, Bohmer C, Amato D, et al. Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. *Nat Med*. 2013;19:934–8.
74. Muller CP, Reichel M, Muhle C, Rhein C, Gulbins E, Kornhuber J. Brain membrane lipids in major depression and anxiety disorders. *Biochim Biophys Acta*. 2015;1851:1052–65.
75. MacQueen GM, Rosebush PI, Mazurek MF. Neuropsychiatric aspects of the adult variant of Tay-Sachs disease. *J Neuropsychiatry Clin Neurosci*. 1998;10:10–9.

76. Cole AL, Lee PJ, Hughes DA, Deegan PB, Waldek S, Lachmann RH. Depression in adults with fabry disease: a common and under-diagnosed problem. *J Inher Metab Dis*. 2007;30:943–51.
77. Laney DA, Gruskin DJ, Fernhoff PM, Cubells JF, Ousley OY, Hipp H, et al. Social-adaptive and psychological functioning of patients affected by Fabry disease. *J Inher Metab Dis*. 2010;33:573–81.
78. Sadek J, Shellhaas R, Camfield CS, Camfield PR, Burley J. Psychiatric findings in four female carriers of fabry disease. *Psychiatr Genet*. 2004;14:199–201.
79. Packman W, Wilson Crosbie T, Riesner A, Fairley C, Packman S. Psychological complications of patients with Gaucher disease. *J Inher Metab Dis*. 2006;29:99–105.
80. MahmoudianDehkordi S, Ahmed AT, Bhattacharyya S, Han X, Baillie RA, Arnold M, et al. Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. *Transl Psychiatry*. 2021;11:153.
81. Awuchi C. Sugar Alcohols: Chemistry, Production, Health Concerns and Nutritional Importance of Mannitol, Sorbitol, Xylitol, and Erythritol. *Int J Adv Acad Res*. 2017;3:2488–9849.
82. Ledochowski M. BWHBTPDF. Fructose- and Sorbitol-reduced diet improves mood and gastrointestinal disturbances in fructose malabsorbers. *Scand J Gastroenterol*. 2000;35:1048–52.
83. Janowsky DS, el-Yousef MK, Davis JM. Acetylcholine and depression. *Psychosom Med*. 1974;36:248–57.
84. Hirsch MJ, Wurtman RJ. Lecithin consumption increases acetylcholine concentrations in rat brain and adrenal gland. *Science*. 1978;202:223–5.
85. Magil SG, Zeisel SH, Wurtman RJ. Effects of ingesting soy or egg lecithins on serum choline, brain choline and brain acetylcholine. *J Nutr*. 1981;111:166–70.
86. Callaerts-Vegh Z, Leo S, Vermaercke B, Meert T, D'Hooge R. LPA5 receptor plays a role in pain sensitivity, emotional exploration and reversal learning. *Genes Brain Behav*. 2012;11:1009–19.
87. Moreno-Fernandez RD, Perez-Martin M, Castilla-Ortega E, Rosell Del Valle C, Garcia-Fernandez MI, Chun J, et al. maLPA1-null mice as an endophenotype of anxious depression. *Transl Psychiatry*. 2017;7:e1077.
88. Saldanha D, Kumar N, Ryali V, Srivastava K, Pawar AA. Serum serotonin abnormality in depression. *Med J Armed Forces India*. 2009;65:108–12.
89. Wood K, Harwood J, Coppen A. The effect of antidepressant drugs on plasma kynurenine in depressed patients. *Psychopharmacology (Berl)*. 1978;59:263–6.
90. Alvarez JC, Gluck N, Fallet A, Gregoire A, Chevalier JF, Advenier C, et al. Plasma serotonin level after 1 day of fluoxetine treatment: a biological predictor for antidepressant response? *Psychopharmacology (Berl)*. 1999;143:97–101.
91. Inoshita M, Umehara H, Watanabe SY, Nakataki M, Kinoshita M, Tomioka Y, et al. Elevated peripheral blood glutamate levels in major depressive disorder. *Neuropsychiatr Dis Treat*. 2018;14:945–53.
92. Ogawa S, Koga N, Hattori K, Matsuo J, Ota M, Hori H, et al. Plasma amino acid profile in major depressive disorder: analyses in two independent case-control sample sets. *J Psychiatr Res*. 2018;96:23–32.
93. Ali-Sisto T, Tolmunen T, Viinamaki H, Mantyselka P, Valkonen-Korhonen M, Koivumaa-Honkanen H, et al. Global arginine bioavailability ratio is decreased in patients with major depressive disorder. *J Affect Disord*. 2018;229:145–51.
94. Rotroff DM, Corum DG, Motsinger-Reif A, Fiehn O, Bottrel N, Drevets WC, et al. Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. *Transl Psychiatry*. 2016;6:e894.
95. Guerreiro JR, Lameu C, Oliveira EF, Klitzke CF, Melo RL, Linares E, et al. Argininosuccinate synthetase is a functional target for a snake venom antihypertensive peptide: role in arginine and nitric oxide production. *J Biol Chem*. 2009;284:20022–33.
96. Bahri S, Zerrouk N, Aussel C, Moinard C, Crenn P, Curis E, et al. Citrulline: from metabolism to therapeutic use. *Nutrition*. 2013;29:479–84.
97. Fewell Z, Davey Smith G, Sterne JA. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. *Am J Epidemiol*. 2007;166:646–55.
98. Nath AP, Ritchie SC, Byars SG, Fearnley LG, Havulinna AS, Joensuu A, et al. An interaction map of circulating metabolites, immune gene networks, and their genetic regulation. *Genome Biol*. 2017;18:146.

ACKNOWLEDGEMENTS

Rotterdam Study: The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and

Sports, the European Commission (DG XII) and the Municipality of Rotterdam. The Exome Sequencing data set was funded by the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) sponsored Netherlands Consortium for Healthy Aging (NCHA; project number 050-060-810), by the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC and by the and by a Complementation Project of the Biobanking and Biomolecular Research Infrastructure Netherlands (BBMRI-NL; www.bbMRI.nl; project number CP2010-41). We are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists. The generation and management of the exome sequencing data for the Rotterdam Study was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, The Netherlands. We thank Mr Pascal Arp, Ms Mila Jhamai and Mr Marijn Verkerk for their help in creating the RS-Exome Sequencing database. **SHIP-Trend:** This work was funded by grants from the German Federal Ministry of Education and Research (BMBF, grants 01ZZ0403, 01ZZ0103, 01GI0883, Athero-SysMed 03IS2061B), the Ministry for Education, Research and Cultural Affairs, as well as the Ministry of Social Affairs of the Federal State of Mecklenburg-West Pomerania. This work is also part of the research project Greifswald Approach to Individualized Medicine (GANI_MED). The GANI_MED consortium is funded by the Federal Ministry of Education and Research and the Ministry of Cultural Affairs of the Federal State of Mecklenburg-West Pomerania (03IS2061A). This work was also funded by the German Research Foundation (DFG: GR1912/11-1). **KORA:** The KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ. K.S. was supported by the Biomedical Research Program at Weill Cornell Medicine in Qatar, a program funded by the Qatar Foundation. **EPIC-Norfolk:** The EPIC-Norfolk study (<https://doi.org/10.22025/2019.10.105.00004>) has received funding from the Medical Research Council (MR/N003284/1, MC-UU_12015/1 and MC_UU_00006/1) and Cancer Research UK (C864/A14136). Metabolite measurements in the EPIC-Norfolk study were supported by the MRC Cambridge Initiative in Metabolic Science (MR/L00002/1) and the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement no. 115372. We are grateful to all the participants who have been part of the project and to the many members of the study teams at the University of Cambridge who have enabled this research. **NEO study:** The NEO study is supported by the participating Departments, the Division and the Board of Directors of the Leiden University Medical Centre, and by the Leiden University, Research Profile Area 'Vascular and Regenerative Medicine'. Dennis Mook-Kanamori is supported by Dutch Science Organization (ZonMW-VENI Grant 916.14.023). The authors of the NEO study thank all participants, all participating general practitioners for inviting eligible participants, all research nurses for data collection, and the NEO study group: Pat van Beelen, Petra Noordijk and Ingeborg de Jonge for coordination, lab and data management. **PREdict study:** Metabolic profiling was conducted by the Mood Disorder Precision Medicine Consortium (MDPMC) funded in part by National Institute of Mental Health (NIMH) - R01MH108348 (PIs: Kaddurah-Daouk, Dunlop). Funding for the PREdict study derives from two grants from the National Institute of Mental Health. A Centers for Intervention Development and Applied Research (CIDAR) grant (P50 MH077083; PI: Helen Mayberg, MD) established the center and provided funds to assess participants for predictors of acute response. A subsequent grant (R01 MH080880; PI: W Edward Craighead, PhD) provided funding to treat non-remitters to the first treatment with combination medication and psychotherapy, to allow follow-up of patients for up to two years to identify predictors of recurrence, and to add patients to the sample to adequately power these studies. Siamak Mahmoudian Dehkordi, Almut Heinken and Ines Thiele are part of Alzheimer Disease Metabolomics Consortium and Mood Disorder Precision Medicine Consortium that funded Predict metabolomics analysis and the AGORA2 analysis.

AUTHOR CONTRIBUTIONS

AS, NA, CD designed the study. AS, IDS, BK, MP, TA, FG, PGH, SMD, AH, NA performed the data analyses. AS, IDS, BK, MP, TA, FG, PGH, SMD, AH, SK, HJG, DOMK, CL, CMD, NA were involved in the interpretation of the data. AIL, KHL, GK, JH, RM, KaSu, CG, KoSt, HV, TM, AF, MW, AP, FRR were involved in the data generation and/or phenotyping. MAI, RKD, NJW, TDS, SK, HJG, DOMK, CL, CMD, NA supervised the work. AS, NA, CMD drafted the manuscript. All authors substantively revised the manuscript and approved the submitted version of the manuscript.

COMPETING INTERESTS

The authors declare the following competing interests: AS is an employee and option holder of SkylineDx B.V. Dennis Mook-Kanamori works as a part-time clinical research consultant for Metabolon, Inc. HJG has received travel grants and speakers' honoraria

from Fresenius Medical Care, Servier, Neuraxpharm and Janssen Cilag. HJG has received research funding from the German Research Foundation (DFG), the German Ministry of Education and Research (BMBF), the DAMP Foundation, Fresenius Medical Care, the EU "Joint Programme Neurodegenerative Disorders (JPND) and the European Social Fund (ESF)". G.K. is co-inventor (through Duke University/Helmholtz Zentrum München) on patents on applications of metabolomics in diseases of the central nervous system; G.K. holds equity in Chymia LLC and IP in PsyProtix and Atai that are exploring the potential for therapeutic applications targeting mitochondrial metabolism in depression. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41380-023-02180-2>.

Correspondence and requests for materials should be addressed to Najaf Amin.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023